These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 20160534)

  • 61. Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!
    Khanna D; McLaughlin V
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1032-3. PubMed ID: 26517415
    [No Abstract]   [Full Text] [Related]  

  • 62. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
    Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
    Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
    Ding Y; Qian J; Zhang S; Xu D; Leng X; Zhao J; Wang Q; Zhang W; Tian X; Li M; Zeng X
    Int J Rheum Dis; 2022 Sep; 25(9):982-990. PubMed ID: 35699128
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
    Ahmadi-Simab K; Lamprecht P; Hellmisch B; Gross WL
    Z Rheumatol; 2004 Dec; 63(6):495-7. PubMed ID: 15605216
    [No Abstract]   [Full Text] [Related]  

  • 66. [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
    Batyraliev TA; Makhmutkhodzhaev SA; Ekinsi E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
    Kardiologiia; 2007; 47(7):73-82. PubMed ID: 18260899
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Savale L; Yaïci A; Natali D; Jaïs X; Parent F; Montani D; Humbert M; Simonneau G; Sitbon O
    Expert Opin Pharmacother; 2011 Jul; 12(10):1585-96. PubMed ID: 21504371
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Associations Between Sildenafil Use and Changes in Days of Hospitalization in a Population With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
    Yang X; Sanders KN; Mardekian J; Mychaskiw MA; Thomas J
    Clin Ther; 2015 May; 37(5):1055-63. PubMed ID: 25818118
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
    Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
    Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pulmonary arterial hypertension in children: a medical update.
    Rosenzweig EB; Barst RJ
    Indian J Pediatr; 2009 Jan; 76(1):77-81. PubMed ID: 19391006
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
    Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P; Amoura Z; Langleben D
    Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
    Dawson A; Reddecliffe S; Coghlan C; Schreiber BE; Coghlan JG
    Eur J Cardiovasc Nurs; 2018 Oct; 17(7):612-618. PubMed ID: 29641223
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Pulmonary arterial hypertension with connective tissue diseases].
    Fukaya S; Yoshida S
    Nihon Rinsho; 2008 Nov; 66(11):2200-4. PubMed ID: 19051743
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
    Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
    Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
    Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pulmonary arterial hypertension (PAH) in connective tissue diseases.
    Kähler CM; Colleselli D
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii11-3. PubMed ID: 16987822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.